BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.
(NASDAQ: INMB) (the“Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XProTM): INKmuneTM Platform: Corporate: Upcoming Events and Milestones: Financial Results for the Third Quarter Ended September 30, 2024: Earnings Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.
Date: October 31, 2024 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): 1-203-518-9843 Conference ID: INMUNE A live audio webcast of the call can be accessed by clicking here or using this link: INmune Bio, Inc. Third Quarter 2024 Earnings Call - 1692115 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 8, 2024, by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no.
11156467. About XProTM XProTM is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it.
